NIVF Overview

NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.

Wall Street analysts forecast NIVF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NIVF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NewGenIvf Group Ltd revenue for the last quarter amounts to 1.28M USD, decreased -12.94

NewGenIvf Group Ltd. EPS for the last quarter amounts to 97.28 USD, decreased -430.88

NewGenIvf Group Ltd (NIVF) has 76 emplpoyees as of March 03 2026.

Today NIVF has the market capitalization of 769.45K USD.